Boswellia serrata extract

New study demonstrates lower dose of botanical blend provides quick pain relief. KOCHI, India, Oct. 18, 2022 /PRNewswire/ -- Results of a third clinical study reveal that Arjuna Natural Pvt. Ltd.'s Rhuleave-K® is also effective in pain relief at a dosage 50% that of the previous two studies. The blend of pure extracts of frankincense (Boswellia serrata) and turmeric (Curcuma longa) already was recognized in the first studies as providing relief of acute musculoskeletal pain following exercise, demonstrating a strong cumulative pain relief effect at 1,000mg. In response to the impressive results of the current study, the researchers note that it was encouraging to find that Rhuleave-K® works well even at 500mg. Continue Reading Rhuleave-K Demonstrates Significant Pain Relief at Half the Dose The earlier, multicenter study, using Rhuleave-K® 1000mg in subjects with acute musculoskeletal pain, was published with 88 subjects in 2020, and repeated in 232 individuals in March 2022. This also brought to the conclusion that Rhuleave-K® is effective equally for relieving musculoskeletal pain in the head and neck, the upper and lower limbs, the trunk, and throughout the body. The recent study[1], published in June 2022 in the Journal of Dental and Medical Sciences led by Jerrin Kizhakkekara, MD, and Saif Mohammad, MD, was a prospective randomized double-blind study with 40 subjects, receiving either a single dose of 500 mg of Rhuleave-K standardized curcuminoids and acetyl ketoboswellic acid (AKBA), or a placebo. The primary outcome was the sum of pain intensity difference at 6 hours, as evaluated by the Numerical Rating Scale (NRS), and total pain relief (TOTPAR6) evaluated by categorical pain relief scale (PRS) every 30 minutes over 6 hours. Results showed a significant decrease (62%) in pain intensity for Rhuleave-K®, with total pain relief 84% better than with the placebo. There was a 43% improvement in the quality of pain relief compared to placebo, as assessed by the McGill short-form questionnaire. The researchers concluded that Rhuleave-K® at the 500mg dose had significant and cumulative pain-relief properties. Joint and tendon pain is one of the leading causes of visits to health and medical practitioners. As a discipline, pain management has become a primary category for specialization. Typically, persons suffering from such pain—whether from overexertion, injury, or inflammation—turn to over-the-counter analgesics, such as aspirin or paracetamol. But such medicines, while generally safe, can have undesired side effects and risks. Increasingly, consumers are seeking more natural solutions to address physical health needs. "There was a distinct gap in the herbal space for fast relief of acute pain," remarks Benny Antony, PhD, Joint Managing Director for Arjuna. "Rhuleave-K® is composed of all-natural botanicals, well-known in traditional Indian medicine and has seen growing support from the scientific community for their strong anti-inflammatory capacity. But more than anti-inflammatory, it's the analgesic—or nociceptive—action which makes Rhuleave K® stand out. And being able to halve the dose makes it extremely affordable, opening more options for creating new formulations using Rhuleave-K®." A third, base component, black sesame seed oil, is employed as an effective carrier agent for the two compounds and has been recognized itself for specific anti-inflammatory and warming properties. "These ingredients were not as successful individually for fast relief of pain," explains Antony. "To our knowledge, Rhuleave-K® —crafted through Arjuna's proprietary SPEEDTECH process—is the first such blend of botanicals clinically documented to offer fast pain relief in acute musculoskeletal pain and pain following exercise." Arjuna's scientists already are looking into other types of pain, such as headaches, that could benefit from the powerful, long-lasting relief Rhuleave-K® offers. About Arjuna Natural Pvt, Ltd. For more than three decades, Arjuna Natural (Arjuna Natural Private Limited.) has been an innovative, science-based organization specializing in natural extracts for Health and sustainable living. The company always sought to serve the unmet needs by bettering lives across the globe through innovative natural solutions. Established in 1992, the company has grown rapidly, with customers in 64 countries, and has an advanced research facility that works in collaboration with international universities on phytochemistry, pharmacokinetics, formulation, development, pre-clinical and toxicity studies. Arjuna Natural's facilities comply with the highest world standards, are GMP-certified, and have ISO, NSF, and halal and Star-K kosher certification. Arjuna will showcase Rhuleave-K® and other branded ingredients at CPHI, Frankfurt, on November 1-3, booth #110F82 and at SupplySide West, Las Vegas, on November 2-3, booth #3228. For further information please contact: [1] Photo - SOURCE Arjuna Natural Ltd.

Patented Boswellia serrata complex improves joint comfort and enhances and improves joint function MORRISTOWN, N.J., July 20, 2022 /PRNewswire/ -- PLT Health Solutions, Inc announced the publication of a clinical study on its Boswellia serrata-based AprèsFlex® 5-Day Joint Support ingredient that provides further evidence of its ability to support joint health and function with statistically significant improvements in pain scores and biomarkers starting at only five days from initial consumption. Published in The Journal of the American Nutrition Association, the study is entitled "Efficacy and Safety of Aflapin®, a Novel Boswellia Serrata Extract, in the Treatment of Osteoarthritis of the Knee: A Short-Term 30-Day Randomized, Double-Blind, Placebo-Controlled Clinical Study"[1] and authored by Vasu Karlapudi, Krishna Bhagavan Sunkara, Purna Rajeswari Konda, Kadainti V. Sarma, and Meher Prasanna Rokkam. Aflapin is an alternative trade name for the AprèsFlex ingredient that is marketed globally by PLT Health Solutions. This is the third double-blind placebo controlled study conducted with AprèsFlex and the second study to confirm statistically significant improvements in joint comfort beginning at five days from a remarkably low dose – 100 mg/day. The ingredient is produced by PLT innovation partner Laila Nutraceuticals (Krishna, Andhra Pradesh, India). Continue Reading According to Dr. Jeremy Appleton, Director of Medical and Scientific Affairs: "We now have three double-blind placebo-controlled clinical trials that validate the efficacy of AprèsFlex, and two demonstrating improvements as early as five days, at a low dose. These outcomes support our customers' "fast-acting" claims for their products containing AprèsFlex." According to Seth Flowerman, President & CEO of PLT Health Solutions, this new study further builds on the strong existing data supporting AprèsFlex as a powerful and fast-acting, low-dose joint health ingredient. "When it comes to mobility, there can be a disconnect between what consumers want and what existing solutions deliver. Too often, natural joint and muscle health solutions require large doses that take weeks or even months to show improvements - and the science backing these ingredients doesn't support what consumers are looking for. That is one of the reasons we continually work to understand things like mechanism of action and to develop quality science that can support strong messaging," he said. "At PLT, we are working to deliver Mobility Solutions, and to make these solutions available for people of all ages and walks of life," he added. Patented formulation combats inflammation AprèsFlex is a patented, synergistic combination of two proprietary extracts derived from Boswellia serrata gum resin, launched in 2013. The oral bioavailability of acetyl-11-keto-beta-boswellic acid (AKBA) from AprèsFlex is significantly higher than that of other commercially available Boswellia extracts, which allows for a lower daily dose, with enhanced efficacy. In joint health products, AprèsFlex is used often as a standalone ingredient or in conjunction with other ingredients to power some of the best-known joint health consumer brands in the world. It has been the subject of seven pre-clinical studies and three published human clinical trials. Third study provides confirmation of fast-acting relief and sheds light on key biomarkers In the newest clinical study, Karlapudi and colleagues examined the efficacy of AprèsFlex in the management of joint comfort and function in a randomized, double-blind, placebo clinical trial. Sixty-seven subjects received either 100 mg/day of AprèsFlex or a matching placebo for thirty days. Measurements included: Visual Analog Score (VAS) The Lequesne algofunctional index (LFI) The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Serum biomarkers (MMP3, TNF, hsCRP, COMP, CPII and C2C) Measurements were done on Days 0, 5 and 30. The study showed that AprèsFlex provided significant improvement (p<0.05) in all pain and physical function scores at five days compared to placebo. Post-trial, VAS, LFI, WOMAC pain, WOMAC stiffness, WOMAC function, and total WOMAC scores decreased in the AprèsFlex group by 45%, 40.9%, 44.4%, 66.3%, 44.4%, and 48%, respectively. Beyond joint comfort and function improvements, AprèsFlex was also shown to offer statistically significant impact on biological markers associated with joint health and inflammation metabolism, including TNF-alpha, C-Reactive Protein (CRP), and Interleukin-6 (IL-6). It was also shown to significantly inhibit matrix metalloproteinase (MMP-3), an enzyme that breaks down cartilage, collagen, and connective tissue. Previous studies with AprèsFlex showed 56% reduction in pain scores at 30 days. A similar study with AprèsFlex showed a 69% reduction in pain scores at 90 days. According to Dr. Jeremy Appleton, Director of Medical and Scientific Affairs for PLT, this new study confirms previous results with AprèsFlex and should give innovators of joint health and mobility products confidence in the fast-acting messaging supported by the science. "We now have three double-blind placebo-controlled clinical trials that validate the efficacy of AprèsFlex, and two demonstrating improvements as early as five days, at a low dose. These outcomes support our customers' "fast-acting" claims for their products containing AprèsFlex. At PLT Health Solutions, we are continually evaluating our existing science and conducting new research that enables our customers to offer strong messaging while building trust with their own customers," he said. In addition to this new stand-alone study on AprèsFlex, ingredient company Bioiberica announced an open-label study in June 2022 that combined AprèsFlex with its Collavant® n2 type-II collagen complex. That study further demonstrated the five-day efficacy of AprèsFlex at 100 mg/day, when used as part of a combination formula Dr. Appleton commented, "The Karlapudi study, along with the new study announced by Bioiberica, continues to strengthen the evidence that AprèsFlex can rapidly improve people's lives." To learn more about AprèsFlex, contact the company or visit the PLT website at . [1] Karlapudi V, Sunkara KB, Konda PR, Sarma KV, Rokkam MP. Efficacy and Safety of Aflapin®, a Novel Boswellia Serrata Extract, in the Treatment of Osteoarthritis of the Knee: A Short-Term 30-Day Randomized, Double-Blind, Placebo-Controlled Clinical Study [published online ahead of print, 2022 Feb 15]. J Am Nutr Assoc. 2022;1-10. doi:10.1080/07315724.2021.2014370 SOURCE PLT Health Solutions